Clinical Trial Search

Primary: The Rate of Change in the Area of EZ Area of Loss From Baseline Through Month 24 — 0.075; 0.166 mm^2 — p=<0.0001

Primary: The Rate of Change in the Area of EZ Area of Loss From Baseline Through Month 24 — 0.111; 0.160 mm^2 — p=0.0186

Primary: Frequency of Ocular and/or Non-ocular Treatment Emergent Adverse Events — 26; 26; 6; 13 Participants

Primary: Visual Acuity Change From Baseline to Month 12 of the Study — 0.1; -0.05 LogMAR Unit

Primary: Ellipsoid Zone (Area of IS/OS Loss) - Cohort 1 — 0.697; 0.629; 1.37; 1.137 mm2

Primary: Number of Patients With no Disease Activity at Week 16 in the Study Eye — 89 Participants

Primary: Area of Lesion Measured by Optical Coherence Tomography Angiography (OCTA) Scan. — 1.07 mm^2

Primary: Change in Macular Drusen Volume — 0.05; 0.11; 20.0; 9.0 mm^3

Primary: BCVA Response Defined as an Increased in 10 Letters at 1 Year Post-implant — 3; 3; 1; 9 eyes

Primary: Percentage of Subjects With Vision Loss to 20/40 or Worse — 5; 3 Eyes — p=.76

Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA

Primary: Mean Change From Baseline in Visual Acuity — 1.8; 1.0 ETDRS letters

Primary: LL BCVA Score Change From Baseline — 0.7; -0.6; 1.1; -0.8 Letters

Primary: Height (Amplitude) of Multifocal ERG Signal — 2.859 nanovolt/degree^2 — p=<0.05

Primary: The Number of Patients With no Fluid on OCT — 10 participants

Primary: Fundus Autofluorescence Imaging to Measure the Rate of Change in Area of Geographic Atrophy — 0.41; 0.35 mm/year — p=0.39

Primary: Sentence Reading — 58.9; 50.5; 86.2; 49.1 Words per Minute (wpm)

Primary: Number of Participant With Improvement in Foveal Thickness (Macular Fluid) as Measured by Optical Coherence Tomography (OCT) — 36 participants

Primary: Change in Central Subfield Thickness From Baseline at 12 Months — -50.3 µm — p=<0.001

Primary: Rod Sensitivity Within the Central Retina as Measured on the Nidek MP-3S — 7; 20 Participants — p=<0.05

Primary: Change in Central Retinal Thickness (CRT) — 384.62; 374; 349.15; 357.62 micrometer

Primary: Change in Lesion Area of Treated Telangiectasia. — -6; -8 mm^2

Primary: The Change in Best-corrected Visual Acuity (BCVA) From Baseline to Year 2 for All Participants. — 0.2; -11.3 ETDRS Letters

Primary: Level of Alpha Melanocyte Stimulating Hormone as Measured by Enzyme-linked Immunosorbent Assay

Primary: Change in Mean Central Subfield Thickness (CST) — -36.6; 1.7 microns — p=0.04

Primary: Development of Advanced AMD in People at Moderate to High Risk for Progression. — 493; 468; 507; 472 Eyes — p=<0.013

Primary: Number of Participants With Systemic Drug-related Adverse Events — 3; 0 participants

Primary: Number of Participants With Ocular Adverse Events in the Study Eye — 51; 64; 63; 60 participants

Primary: Mean Change in Best Corrected Visual Acuity (BCVA) at Month 6 — 7.24; -0.43; 3.8 Mean letter change in BCVA

Primary: Visual Acuity (VA) — 8.51; 8.72; 8.67; 8.93 lines of VA